Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2022-06-13 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2022年度向特定对象发行A股股票方案论证分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Betta Pharmaceuticals Co., Ltd regarding a 2022 private placement of A shares to specific investors. It includes background, purpose, legal compliance, pricing, issuance procedures, fairness, and impact analysis. The content focuses on a capital raising activity through a non-public issuance of shares, discussing the rationale, regulatory compliance, pricing methodology, and shareholder approval process. There are no financial statements or earnings data, nor is it a general regulatory announcement or a brief notice. The document is a comprehensive analysis and explanation of a capital/financing update related to a specific share issuance. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-06-13 Chinese
监事会对公司向特定对象发行A股股票的书面审核意见
Audit Report / Information Classification · 95% confidence The document is a written audit opinion from the Supervisory Board regarding the company's private placement of A shares to specific investors. It references compliance with company law, securities law, and regulatory rules related to stock issuance. The content focuses on the legality, feasibility, and fairness of the private placement, including the use of proceeds and related party transactions. It does not contain financial statements or detailed financial results, nor is it a general announcement or a report publication notice. This type of document is a formal audit or supervisory opinion related to a specific financing activity, which fits the category of Audit Report / Information (AR). The document length is short and it is not a mere announcement or certification, so it is not RPA or RNS. Therefore, the best classification is AR with high confidence. FY 2022
2022-06-13 Chinese
未来三年（2022-2024年）股东回报规划
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the company 贝达药业股份有限公司 regarding its shareholder return plan for the years 2022-2024. It details the company's dividend policy, principles for profit distribution, decision-making mechanisms, and conditions for cash and stock dividends. The document is an official public announcement outlining the company's planned approach to shareholder returns over a multi-year period. It does not contain financial statements, audit information, or detailed financial results. It is not a report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple notification of a report publication. The document is a regulatory announcement about the company's dividend policy and shareholder return planning, which fits best under Regulatory Filings (RNS) as it does not fit more specific categories such as Notice of Dividend Amount (DIV) because it is a multi-year plan rather than a specific dividend declaration. The document length is under 5,000 characters, and it is a detailed announcement rather than a report or certification. Therefore, the best classification is Regulatory Filings (RNS).
2022-06-13 Chinese
关于2018年（第二期）股票期权激励计划部分预留授予股票期权注销完成的公告
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the cancellation of a portion of reserved stock options under a 2018 stock option incentive plan. It details the reasons for cancellation, the number of options affected, and confirms completion of the cancellation process. There is no financial data, no report attached or referenced as being published, and no mention of a meeting or voting results. The content relates to changes in stock option incentives, which is a capital structure update but not a new share issue or dividend. This fits best under Capital/Financing Update (CAP) as it concerns changes in the company's capital incentive plans.
2022-06-09 Chinese
关于2018年（第二期）股票期权激励计划部分首次授予股票期权注销完成的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the cancellation of a portion of stock options granted under the company's 2018 stock option incentive plan. It details the number of stock options cancelled, reasons for cancellation, and confirms completion of the cancellation process. There is no financial report, earnings data, or management discussion. The document is a formal announcement related to share-based compensation adjustments, specifically about stock option cancellations. This fits best under the category of Share Issue/Capital Change (SHA), as it involves changes in the company's capital structure through stock option cancellations.
2022-06-09 Chinese
关于2018年（第一期）股票期权激励计划首次授予股票期权第三个行权期满未行权股票期权注销完成的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the cancellation of unexercised stock options from a 2018 stock option incentive plan. It details the board meeting decisions and regulatory compliance related to the stock option cancellation. There is no financial report, earnings data, or detailed financial analysis. The document is a formal announcement about a capital structure-related event (stock option cancellation) but does not announce new share issuance or repurchase. It fits best under the category of Share Issue/Capital Change (SHA) because it relates to changes in the company's capital structure through stock option cancellations.
2022-06-09 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.